Evidence map›Paper›PMID 40205601›Full record

SynthesisJournal of health, population, and nutrition2025

Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale.

Khushbu Viresh Janani, Parsa Saberian, Hardik B Patel, Narsimha Rao Keetha, Ardalan Etemadzadeh, Anya Patel, Seyyed Mohammad Hashemi, Ehsan Amini-Salehi, Anoop Gurram

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khushbu Viresh JananiSoundview Medical Associates, Department of Internal Medicine, Hartford Healthcare, 50 Danbury Road, Wilton, CT, 06612, USA.
Parsa SaberianCardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Hardik B PatelDepartment of Internal Medicine, Yale New Haven Health Bridgeport Hospital, 267 Grant Street, Bridgeport, CT, 06610, USA.
Narsimha Rao KeethaOhio Kidney and Hypertension Center, 7255, Old Oak Blvd, Ste C111 Middleburg Hts, Fairview Park, OH, 44130, USA.
Ardalan EtemadzadehCardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Anya Patel, Nashua High School South 36 Riverside St, Nashua, NH, 03062, USA.
Seyyed Mohammad HashemiCardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. mohammadhashemi281@gmail.com.
Ehsan Amini-SalehiGastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. ehsanaminisalehi1998@gmail.com.
Anoop GurramDepartment of Hospital Medicine, Cleveland Clinic, 33300 Cleveland Clinic Blvd, Avon, Ohio, ashua, NH, 44011, 03062, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic syndrome (MetS) is a cluster of metabolic abnormalities that increase the risk of cardiovascular diseases (CVD). Patients with inflammatory bowel disease (IBD) may be at higher risk of developing MetS due to chronic inflammation, altered adipokine profiles, and the effects of corticosteroid treatment. However, the prevalence of MetS in IBD patients remains inconsistent across studies. This meta-analysis aims to estimate the prevalence of MetS in IBD patients and compare its occurrence between Crohn's disease (CD) and ulcerative colitis (UC).

methodsA systematic search was conducted across PubMed, Scopus, Embase, and Web of Science from their inception up to January 19, 2025. Eligible observational studies reporting MetS prevalence in IBD patients were included. Meta-analysis was performed using a random-effects model, with heterogeneity assessed via the I² statistic. Comprehensive Meta-Analysis (CMA) software, version 4.0 was used for analysis.

resultsThe pooled prevalence of MetS in IBD patients was 21.8% (95% CI: 14.3-31.6%). The prevalence was higher in UC patients (32.7%, 95% CI: 16.0-55.5%) compared to CD patients (14.1%, 95% CI: 8.6-22.3%). Patients with UC had significantly higher odds of MetS than those with CD (OR = 1.38, 95% CI: 1.03-1.85, P = 0.02). Additionally, IBD patients with MetS were significantly older than those without (MD: 9.89, 95% CI: 5.12-14.67, P < 0.01).

conclusionIn summary, this meta-analysis reveals a notable prevalence of MetS among patients with IBD, particularly in those with UC, where the prevalence is higher than in CD. The analysis also shows that IBD patients with MetS tend to be older, suggesting age as a contributing factor. These findings underscore the need for routine metabolic screening in IBD care, especially in UC and elderly patients.

Indexed as

Inflammatory Bowel DiseasesMetabolic SyndromeAdultColitis, UlcerativeCrohn DiseaseFemaleGlobal HealthHumansMalePrevalenceRisk FactorsCrohn’s diseaseInflammatory bowel diseaseMeta-analysisMetabolic syndromeUlcerative colitis

Identifiers

PMID40205601
PMCPMC11983980

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.